Diasome Pharmaceuticals Announces First Closing of Series C Financing Round

December 07, 2023 08:39 PM CET | By EIN Presswire
Follow us on Google News:

Diasome Secures Series C Funding with Eli Lilly Participation

CLEVELAND, OH, USA, December 7, 2023 /EINPresswire.com/ -- Diasome Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company that leverages a novel hepatocyte cell targeting platform to develop innovative therapies for diabetes, obesity, and other metabolic disorders, has announced the first closing of its Series C financing today. This funding round, led by current investors, also includes participation from Eli Lilly and Company.

"We are gratified by the confidence shown in our work by the investors involved in this new funding," said Robert Geho, CEO of Diasome Pharmaceuticals. "This financing supports our ongoing clinical research and advancement of transformative treatments for people living with diabetes and other metabolic disorders."

Diasome is preparing to initiate its OPTI-2 trial, a Phase 2b, double-blinded, randomized controlled trial in people with type 1 diabetes. The OPTI-2 trial will investigate the effect of Diasome's HDV™ Insulin compared to standard of care insulin therapy on blood glucose control and hypoglycemia prevention over a six-month treatment period.

Diasome's pipeline features multiple innovative assets, including a low-dose oral incretin delivery system that explores the benefits of balanced hepatic and peripheral targeting. Additionally, the pipeline includes a novel hepatocyte-targeted drug strategy aimed at modulating a key underlying mechanism of type 2 diabetes.

About Diasome Pharmaceuticals, Inc.: Diasome Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company pioneering hepatocyte cell drug targeting to restore hepatocyte metabolism and treat metabolic diseases. Diasome's Hepatocyte Targeting Platform reestablishes hepatocyte function, addressing the root cause of dysregulations central to major metabolic diseases such as diabetes, obesity, and dyslipidemia. Diasome aims to deliver superior patient outcomes and enhanced disease management by leveraging the hepatocyte's natural regulatory functions.

For additional details about Diasome Pharmaceuticals, Inc., please visit www.diasome.com

Kent Manson
Diasome Pharmaceuticals
+1 720-891-7644
[email protected]


The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Top ASX Listed Companies

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK